 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
2 News |  |
| 12345» |
- ||| Anniko (penpulimab) / Akesobio, Sino Biopharm
P3 data, Journal, Metastases: First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. (Pubmed Central) - May 2, 2024
P3
The treatment was safe and tolerable. Penpulimab combined with paclitaxel and carboplatin is a new option for first-line treatment in patients with this advanced disease.
- || Retrospective data, Review, Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis. (Pubmed Central) - Apr 16, 2024
For patients with positive PD-L1 expression, Sin?+?CT and Cam?+?CT were found to be optimal for OS and PFS, respectively. It is important to note that, with the exception of Tor?+?CT, the toxicity of the other combinations was higher than that of CT alone.
- |||| Anniko (penpulimab) / Akesobio, Sino Biopharm
Trial primary completion date, Metastases: A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Apr 4, 2024
P3, N=298, Recruiting, Sponsor: Akeso
It is important to note that, with the exception of Tor?+?CT, the toxicity of the other combinations was higher than that of CT alone. Trial primary completion date: Dec 2023 --> Feb 2025
- || ivonescimab (AK112) / Akesobio, Summit Therap
Trial primary completion date, Combination therapy: AK112-201: A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC (clinicaltrials.gov) - Apr 4, 2024
P2, N=296, Recruiting, Sponsor: Akeso
Trial primary completion date: Dec 2023 --> Feb 2025 Trial primary completion date: Mar 2024 --> Dec 2024
- ||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm
Trial completion date, Trial termination, Metastases: AK105-301: A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 4, 2024
P3, N=164, Terminated, Sponsor: Akeso
Trial primary completion date: Mar 2024 --> Dec 2024 Trial completion date: Jun 2024 --> Dec 2023 | Active, not recruiting --> Terminated; corporate strategy adjustment
- ||| Anniko (penpulimab) / Akesobio, Sino Biopharm
Trial completion: AK105-201: A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma (clinicaltrials.gov) - Apr 3, 2024
P1/2, N=94, Completed, Sponsor: Akeso
Trial completion date: Jun 2024 --> Dec 2023 | Active, not recruiting --> Terminated; corporate strategy adjustment Unknown status --> Completed
- || Anniko (penpulimab) / Akesobio, Sino Biopharm
Trial completion: AK105-203: A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Apr 3, 2024
P2, N=31, Completed, Sponsor: Akeso
Unknown status --> Completed Active, not recruiting --> Completed
- ||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm
Trial completion, Metastases: A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 3, 2024
P3, N=350, Completed, Sponsor: Akeso
Active, not recruiting --> Completed Unknown status --> Completed
- ||| Anniko (penpulimab) / Akesobio, Sino Biopharm
Trial completion, Enrollment change, Trial completion date, Combination therapy, Metastases: A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov) - Apr 2, 2024
P2, N=28, Completed, Sponsor: Akeso
Unknown status --> Completed Recruiting --> Completed | N=90 --> 28 | Trial completion date: Jun 2023 --> Dec 2023
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 2, 2024
P2, N=33, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
- || TQB2223 / Sino Biopharm, Anniko (penpulimab) / Akesobio, Sino Biopharm
New P1 trial, Metastases: Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. (clinicaltrials.gov) - Mar 21, 2024
P1, N=34, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- || Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, Journal: Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy. (Pubmed Central) - Mar 4, 2024
We also summarized and reviewed literature reports on PubMed from January 1, 2000, to December 31, 2022, using the keyword "pulmonary blastoma", discussing the efficacy and specifics of chemotherapy and radiotherapy. Immunotherapy, in combination with targeted therapy, should be considered a potential therapeutic strategy for PB.
- || Anniko (penpulimab) / Akesobio, Sino Biopharm
P1/2 data, Journal, Metastases: Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death-1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105-204). (Pubmed Central) - Feb 27, 2024
Penpulimab showed promising antitumor activity with an acceptable safety profile, offering a potential new treatment approach for solid tumors. These findings supported the evaluation of penpulimab's durable activity and safety, as monotherapy or in combination therapy, in specific malignancies.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib + penpulimab plus chemo-less therapy in first-line treatment for persistent, recurrent, or metastatic cervical cancer: a single-arm, phase ? study (ALTN-AK105-II-06) () - Feb 3, 2024 - Abstract #SGO2024SGO_773;
- ||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm, TQB2618 / Sino Biopharm
Enrollment open, Trial initiation date, Monotherapy, Metastases: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection (clinicaltrials.gov) - Jan 23, 2024
P1, N=75, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
These findings supported the evaluation of penpulimab's durable activity and safety, as monotherapy or in combination therapy, in specific malignancies. Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Jan 2024
- | Anniko (penpulimab) / Akesobio, Sino Biopharm
Trial completion date, Metastases: A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jan 3, 2024
P2, N=130, Active, not recruiting, Sponsor: Akeso
Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Jan 2024 Trial completion date: Dec 2023 --> Apr 2024
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Penpulimab combined with anlotinib in patients with R/M HNSCC after failure of platinum-based chemotherapy: a single-arm, multicenter, phase ? study. (Pubmed Central) - Jan 2, 2024
Trial completion date: Dec 2023 --> Apr 2024 Penpulimab combined with anlotinib demonstrated promising efficacy and manageable safety in R/M HNSCC patients after failure of platinum-based chemotherapy.
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: ALTER-GO-020: A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer (clinicaltrials.gov) - Dec 27, 2023
P2, N=86, Recruiting, Sponsor: Sichuan Cancer Hospital and Research Institute
Penpulimab combined with anlotinib demonstrated promising efficacy and manageable safety in R/M HNSCC patients after failure of platinum-based chemotherapy. Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
A phase II study to evaluate the safety and efficacy of anlotinib combined with penpulimab for advanced refractory biliary tract cancer. (Poster Bd # P11) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_360;
P1/2
Based on a two-sided test for one proportion with 5.0% type I error, 80% power to detect an improvement in ORR from 5% to 22%, there will be 27 pts enrolled considering 20% of pts dropping out. Clinical trial information: ChiCTR2300069126.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma. (Poster Bd # P8) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_357;
Secondary endpoints are median PFS and overall survival (OS), disease control rate (DCR) per RECIST 1.1, quality of life (QOL) and safety. Recruitment for this study will complete in December 2024.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial. (Poster Bd # G13) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_236;
More ESCC pts would be recruited in the future. Clinical trial information: ChiCTR2200064848.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial. (Poster Bd # F20) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_224;
The combination of anlotinib plus penpulimab and nab-paclitaxel as first-line therapy for advanced ESCC demonstrated promising efficacy and manageable safety profile. The conclusions needed to be confirmed in subsequent trials.
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: South China Nervous Tumor 00002-2301: The efficacy of anlotinib or penpulimab in patients with progression after concurrent chemoradiotherapy in new diagnosed glioblastoma:a Bayesian adaptive randomized designed phase II stduy (EUDRACT) - Dec 5, 2023
P2, N=164, Recruiting, Sponsor: The First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-Sen University
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Combination therapy, Metastases: ZL-IRIAN: Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC (clinicaltrials.gov) - Dec 4, 2023
P2, N=44, Recruiting, Sponsor: Fudan University
The conclusions needed to be confirmed in subsequent trials. Trial completion date: Jan 2024 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Mar 2024
- || Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal, IO biomarker, Circulating tumor DNA: Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study). (Pubmed Central) - Dec 3, 2023
P2
The addition of anlotinib and penpulimab to XELOX, may contribute to delaying relapse in ctDNA-positive patients. https://www.clinicaltrials.gov, identifier NCT05494060.
- ||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Circulating tumor DNA: EXPLORING: XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma (clinicaltrials.gov) - Nov 7, 2023
P2, N=80, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
https://www.clinicaltrials.gov, identifier NCT05494060. Not yet recruiting --> Recruiting
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
A prospective phase 2 study on efficacy and safety of AK105, anlotinib combined with nab-paclitaxel (nab-P) as a first-line therapy in patients(pts) with advanced triple-negative breast cancer(TNBC) (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_804;
P2
The combination of AK105, anlotinib and nab-P showed better treatment response and tolerable toxicity in the treatment of first-line patients with TNBC. Further studies enrolling more patients are still needed.
- | Anniko (penpulimab) / Akesobio, Sino Biopharm
New P2 trial: Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial (clinicaltrials.gov) - Nov 1, 2023
P2, N=43, Recruiting, Sponsor: Ruijin Hospital
- | 5-fluorouracil / Generic mfg.
Journal, IO biomarker: A case of pancreatic cancer treated with chemotherapy combined with immunotherapy and targeted therapy. (Pubmed Central) - Oct 30, 2023
The patient received two cycles of modified FOLFIRINOX plus immune checkpoint inhibitor (penpulimab)...Three cycles of combined therapy were adopted after surgery followed by maintenance therapy with anlotinib plus penpulimab. There was no evidence of tumor recurrence during the follow-up (nearly 19 months since diagnosis).
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN (clinicaltrials.gov) - Oct 18, 2023
P2, N=48, Recruiting, Sponsor: Eye & ENT Hospital of Fudan University
There was no evidence of tumor recurrence during the follow-up (nearly 19 months since diagnosis). Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jan 2024 --> Dec 2024
- | Anniko (penpulimab) / Akesobio, Sino Biopharm
New P2 trial: Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC (clinicaltrials.gov) - Oct 13, 2023
P2, N=72, Recruiting, Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- | 5-fluorouracil / Generic mfg.
Journal, IO biomarker: A case of pancreatic cancer treated with chemotherapy combined with immunotherapy and targeted therapy. (Pubmed Central) - Oct 9, 2023
The patient received two cycles of modified FOLFIRINOX plus immune checkpoint inhibitor (Penpulimab)...Three cycles of combined therapy were adopted after surgery followed by maintained therapy with anlotinib plus Penpulimab. There was no evidence of tumor recurrence 19 months since diagnosis.
- Anniko (penpulimab) / Akesobio, Sino Biopharm
Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043) (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_998;
P2
There is no fatal AE related to Penpulimab or Anlotinib. Conclusions The results demonstrated that these new perioperative combinations of ICI and Anti-angiogenesis agent (Penpulimab and Anlotinib) with or without chemotherapy showed promising efficacy and with manageable safety profiles.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_718;
P2
Conclusions PAAG as first-line treatment demonstrated a promising efficacy and manageable AEs for mPC. Biomarkers identified in this study possessed the potential to guide the precise clinical application of PAAG.
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial: Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - Oct 2, 2023
P=N/A, N=10, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: RCT-PAAG: Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer (clinicaltrials.gov) - Sep 25, 2023
P2, N=177, Recruiting, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- | paclitaxel / Generic mfg.
New P3 trial, Metastases: A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody (clinicaltrials.gov) - Sep 21, 2023
P3, N=52, Not yet recruiting, Sponsor: Degan Lu
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Combination therapy, Metastases: Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN (clinicaltrials.gov) - Sep 13, 2023
P2, N=48, Recruiting, Sponsor: Eye & ENT Hospital of Fudan University
Biomarkers identified in this study possessed the potential to guide the precise clinical application of PAAG. Active, not recruiting --> Recruiting
- || Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: ALTER-HN005: Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Sep 6, 2023
P2, N=110, Not yet recruiting, Sponsor: Sun Yat-sen University
Active, not recruiting --> Recruiting Trial completion date: Jun 2025 --> Oct 2025 | Initiation date: Jun 2023 --> Oct 2023 | Trial primary completion date: Jun 2024 --> Oct 2024
- ||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm, TQB2618 / Sino Biopharm
New P1 trial, Monotherapy, Metastases: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection (clinicaltrials.gov) - Aug 25, 2023
P1, N=75, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | Anniko (penpulimab) / Akesobio, Sino Biopharm
Enrollment open: Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 23, 2023
P=N/A, N=31, Recruiting, Sponsor: Henan Cancer Hospital
Trial completion date: Jun 2025 --> Oct 2025 | Initiation date: Jun 2023 --> Oct 2023 | Trial primary completion date: Jun 2024 --> Oct 2024 Not yet recruiting --> Recruiting
- || Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm, TQB2618 / Sino Biopharm
New P1 trial, Metastases: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). (clinicaltrials.gov) - Aug 4, 2023
P1, N=40, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- ||| Anniko (penpulimab) / Akesobio, Sino Biopharm, TQB2618 / Sino Biopharm
Enrollment open, Metastases: A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 31, 2023
P1/2, N=60, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || TQB3602 / Sino Biopharm, Anniko (penpulimab) / Akesobio, Sino Biopharm
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers (clinicaltrials.gov) - Jul 27, 2023
P1, N=7, Active, not recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting | N=63 --> 7 | Trial primary completion date: May 2023 --> Dec 2023
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Penpulimab + anlotinib plus chemo-less therapy in first-line treatment for persistent, recurrent, or metastatic cervical cancer: A single-arm, phase II study (ALTN-AK105-II-06) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2325;
Grade ?3 TRAEs incidence was 42.86% (hypertension: 21.43%, neutropenia: 21.43% leukopenia: 14.29%, and hypertriglyceridemia: 7.14%). Conclusions This chemo-less therapy of only 2 cycles of chemotherapy + penpulimab + anlotinib in first-line treatment, maintaining with penpulimab and anlotinib showed promising efficacy with a favourable toxicity profile for patients with persistent, recurrent, or metastatic cervical cancer.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Pulmonary Blastoma is Successfully Treated with Immunotherapy and Targeted Therapy (Exhibit Hall) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1871;
This study shows the combination of immunotherapy and multi-targeting tyrosine kinase inhibitors can produce a more significant clinical response in pulmonary blastoma, or maybe a synergistic effect. As a potential therapeutic strategy for pulmonary blastoma, immunotherapy in combination with targeted therapy should be considered.
- | Anniko (penpulimab) / Akesobio, Sino Biopharm
New P2 trial: Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma (clinicaltrials.gov) - Jul 20, 2023
P2, N=108, Not yet recruiting, Sponsor: Sun Yat-sen University
- || Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, Journal: Penpulimab and anlotinib in an elderly patient with recurrent cervical cancer: a case report and literature review. (Pubmed Central) - Jul 14, 2023
The patient was diagnosed with poorly differentiated stage III C1r cervical squamous cell carcinoma and received standard cisplatin-sensitized chemoradiotherapy, subsequently achieving a good treatment effect of complete response. It has been maintained for more than 17
- || Anniko (penpulimab) / Akesobio, Sino Biopharm
Review, Journal, Checkpoint inhibition: A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab. (Pubmed Central) - Jul 14, 2023
The incidence of CIP is very low, and its diagnosis should be combined with clinical manifestations and previous drug use. mNGS can provide certain value in the exclusion of severe infections, so as to provide basis and reference for the early identification, diagnosis and treatment of severe CIP.
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date, Combination therapy, Metastases: ZL-IRIAN: Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC (clinicaltrials.gov) - Jul 6, 2023
P2, N=44, Recruiting, Sponsor: Fudan University
mNGS can provide certain value in the exclusion of severe infections, so as to provide basis and reference for the early identification, diagnosis and treatment of severe CIP. Trial primary completion date: Jan 2023 --> Sep 2023